Suzan Nakasendwa

Suzan Nakasendwa

Auto-generated profile, based on publicly available information

Suzan Nakasendwa

Makerere University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FSFred C. Semitala
Fred C. Semitala
JKJillian L. Kadota
Jillian L. Kadota
AMAllan Musinguzi
Allan Musinguzi
FWFred Welishe
Fred Welishe
ANAnne Nakitende
Anne Nakitende
ACAdithya Cattamanchi
Adithya Cattamanchi
Background: Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies. Methods and findings: In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (≥11 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher’s exact test (two-sided α = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] p < 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] p < 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] p < 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings. Conclusions: Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers. Trial Registration: ClinicalTrials.gov NCT03934931.

8 November 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
JMJonathan Mayito
Jonathan Mayito
CTConrad Tumwine
Conrad Tumwine
RGRonald Galiwango
Ronald Galiwango
ENElly Nuwamanya
Elly Nuwamanya
SNSuzan Nakasendwa
Suzan Nakasendwa
FKFrancis Kakooza
Francis Kakooza
Background: It is projected that drug-resistant infections will lead to 10 million deaths annually by 2050 if left unabated. Despite this threat, surveillance data from resource-limited settings are scarce and often lack antimicrobial resistance (AMR)–related clinical outcomes and economic burden. We aim to build an AMR and antimicrobial use (AMU) data warehouse, describe the trends of resistance and antibiotic use, determine the economic burden of AMR in Uganda, and develop a machine learning algorithm to predict AMR-related clinical outcomes. Objective: The overall objective of the study is to use data-driven approaches to optimize antibiotic use and combat antimicrobial-resistant infections in Uganda. We aim to (1) build a dynamic AMR and antimicrobial use and consumption (AMUC) data warehouse to support research in AMR and AMUC to inform AMR-related interventions and public health policy, (2) evaluate the trends in AMR and antibiotic use based on annual antibiotic and point prevalence survey data collected at 9 regional referral hospitals over a 5-year period, (3) develop a machine learning model to predict the clinical outcomes of patients with bacterial infectious syndromes due to drug-resistant pathogens, and (4) estimate the annual economic burden of AMR in Uganda using the cost-of-illness approach. Methods: We will conduct a study involving data curation, machine learning–based modeling, and cost-of-illness analysis using AMR and AMU data abstracted from procurement, human resources, and clinical records of patients with bacterial infectious syndromes at 9 regional referral hospitals in Uganda collected between 2018 and 2026. We will use data curation procedures, FLAIR (Findable, Linkable, Accessible, Interactable and Repeatable) principles, and role-based access control to build a robust and dynamic AMR and AMU data warehouse. We will also apply machine learning algorithms to model AMR-related clinical outcomes, advanced statistical analysis to study AMR and AMU trends, and cost-of-illness analysis to determine the AMR-related economic burden. Results: The study received funding from the Wellcome Trust through the Centers for Antimicrobial Optimisation Network (CAMO-Net) in April 2023. As of October 28, 2024, we completed data warehouse development, which is now under testing; completed data curation of the historical Fleming Fund surveillance data (2020-2023); and collected retrospective AMR records for 599 patients that contained clinical outcomes and cost-of-illness economic burden data across 9 surveillance sites for objectives 3 and 4, respectively. Conclusions: The data warehouse will promote access to rich and interlinked AMR and AMU data sets to answer AMR program and research questions using a wide evidence base. The AMR-related clinical outcomes model and cost data will facilitate improvement in the clinical management of AMR patients and guide resource allocation to support AMR surveillance and interventions. International Registered Report Identifier (IRRID): PRR1-10.2196/58116

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
MOMoses Ocan
Moses Ocan
MKMaureen Katusiime
Maureen Katusiime
DKDaniel Kyabayinze
Daniel Kyabayinze
BKBenon Kwesiga
Benon Kwesiga
RARodgers Ayebare
Rodgers Ayebare
AAAlex Riolexus Ario
Alex Riolexus Ario
Background: Coronavirus disease 2019 (COVID-19) vaccination is crucial for healthcare workers (HCWs) and understanding their perspectives is vital for promoting vaccine uptake in communities. Aim: This study assessed factors influencing COVID-19 vaccine uptake among HCWs in Kampala, Uganda. Setting: A cross-sectional study was done in seven high-volume health facilities in Kampala. Methods: A questionnaire based on the Behavioural and Social Drivers Model was administered to 200 HCWs. Data were analysed using STATA version 17 to identify associations with vaccination status. Results: Overall vaccination uptake was 65.2% (95% confidence interval [CI]: 58.1, 71.8), with 17.7% (95% CI: 12.6, 23.7) having received a booster dose. Concerns about safety and side effects were the primary reasons for vaccine hesitancy. While HCWs generally believed that getting vaccinated for diseases such as measles and tuberculosis can help prevent sickness or death, with 70.5% (n = 141/200) strongly agreeing, only 48% (n = 96/200) of HCWs strongly agreed that vaccination against COVID-19 can reduce the risk of illness or death. Age, profession and facility type were associated with vaccination status. Conclusion: Healthcare workers in Kampala had high vaccine uptake, but safety concerns remain. Targeted communication strategies from the Ministry of Health are needed to address these concerns and further increase vaccine confidence. Contribution: This study reveals specific reasons for vaccine hesitancy among HCWs in an African urban setting. These insights inform interventions to improve vaccine uptake in this key population.

9 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
SNSuzan Nakasendwa
Suzan Nakasendwa
JMJonathan Mayito
Jonathan Mayito
VTVivian Twemanye
Vivian Twemanye
CTConrad Tumwine
Conrad Tumwine
RKReuben Kiggundu
Reuben Kiggundu
AKAndrew Kambugu
Andrew Kambugu
Objective: Limited data exist on temporal changes in antibiotic use in low and middle-income countries. We evaluated trends in antibiotic use at tertiary hospitals in Uganda. Design: Retrospective trend analysis of a repeated point prevalence survey (PPS). Setting and participants: This study utilised antibiotic use data from quarterly PPS conducted among inpatients at nine regional referral hospitals in Uganda between October 2020 and December 2023. Outcome measures: We determined the proportions of antibiotic use, prescriptions guided by culture and sensitivity tests (CST), WHO AWaRe ( Access, Watch and Reserve ) categories, and prescriptions without documented indication. Linear regression was used to derive slope coefficients and 95% confidence interval (CI). Results: Of 15,154 patients surveyed, 8,892 (58.7%) received systemic antibiotics. The median age was 23 years (IQR: 11–38), 5,338 (60.5%) were female, and 4,583 (51.5%) were on treatment for infectious syndromes, including sepsis (1,400, 15.7%) and pneumonia (867, 9.8%). The drug utilisation index (DU75) consisted of ceftriaxone, metronidazole, gentamicin and ampicillin, which accounted for 76.9% (12,291/15,989) of total antibiotic use. The distribution of prescribed antibiotics was 46.6% Access, 45.5% Watch, 0.1% Reserve and 7.7% unrecommended combinations. Overall, 5,402 (60.8%) prescriptions were aligned with national guidelines, 2,147 (24.1%) prescriptions were issued without an indication, and CST guided 271 (3%) prescriptions. Over time, there was no significant change in antibiotic prescription prevalence (slope=0.09, CI −0.93 to 1.10) and prescriptions without indication (slope=−0.70, CI −1.79 to 3.98). However, adherence to treatment guidelines (slope=2.06, CI 0.14 to 3.98) and prescriptions based on CST results (slope=0.62, CI 0.12 to 1.13) significantly increased, while ‘ Watch’ antibiotics prescriptions decreased (slope=−0.40, CI −0.63 to –0.17). Conclusions: The antibiotic prescription rate remained high, with no significant change over time. Improvements were seen in adherence to treatment guidelines, use of CST and reduced use of ‘ Watch’ antibiotics. Strengthening antibiotic stewardship is recommended to further improve practices.

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
CSClara Sambani
Clara Sambani
TMTonny Muwonge
Tonny Muwonge
LCLiness Chinyamunyamu
Liness Chinyamunyamu
ADAmon Dembo
Amon Dembo
MFMosoka P. Fallah
Mosoka P. Fallah
MMMitch Matoga
Mitch Matoga
Background: The COVID-19 pandemic led to an urgent need for a global vaccine. Despite being a priority group, the vaccine uptake among healthcare workers (HCWs) remains low. Aim: This article assessed the COVID-19 vaccine uptake and its associated barriers in Malawi. Setting: A cross-sectional study was conducted among HCWs in Malawi’s Blantyre, Lilongwe and Mzuzu districts from 11 April 2023 to 14 April 2023. Methods: Proportionally distributed among various cadres, 200 participants were randomly selected. A structured questionnaire was administered, assessing HCWs’ uptake, willingness, attitudes and barriers to COVID-19 vaccines. Data were managed in REDCap and analysed using STATA version 14. Frequencies and percentages were computed. Variables with p-value ≤ 0.25 were included in the multivariable modified passion model. Results: A total of 175 (88%) participants received a single-dose vaccine, while only 11.5% received a booster. Vaccine uptake was associated with age groups 25–34 years (aPR = 2.35, 95% CI: 1.21, 4.60) and 35–44 years (aPR = 2.30, 95% CI: 1.18, 4.50), being a nurse/midwife (aPR = 0.86, CI: 0.74, 0.99) and laboratory personnel (aPR = 0.86, 95% CI: 0.74, 0.99). Unvaccinated HCWs were concerned about vaccine side effects and lacked trust in the development process. Conclusion: Issues of vaccine safety, side effects and lack of trust in the vaccine should be addressed. Promoting awareness of vaccine development and benefits, targeting all age groups and cadres, is required among HCWs. Contribution: The findings can be utilised to develop specific interventions on age and cadre to promote vaccine acceptance among HCWs, in countries with similar contextual settings to Malawi.

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
RYRichard Brou Yapi
Richard Brou Yapi
GZGuillaume B.Y. Zamina
Guillaume B.Y. Zamina
MBMartial Bama
Martial Bama
YAYao M.R. Amani
Yao M.R. Amani
FKFrancis Kakooza
Francis Kakooza
ITIssaka Tiembré
Issaka Tiembré
Background: Vaccine hesitancy hinders COVID-19 control, especially among healthcare workers (HCWs). Aim: This study examined factors influencing COVID-19 vaccine uptake and hesitancy among HCWs in Abidjan, Côte d’Ivoire. Setting: The study was conducted among healthcare workers in Abidjan, the capital city of Côte d’Ivoire. Methods: A cross-sectional study was conducted from May 2023 to June 2023 in Abidjan. A total of 240 HCWs completed a questionnaire on vaccination attitudes, hesitancy factors and willingness to recommend vaccines. Descriptive statistics and modified Poisson regression estimated adjusted prevalence ratios (aPR) at a 95% confidence interval. Results: Among participants, 57.5% were female, with a median age of 40 years (IQR: 33–45). HCWs included physicians (26.7%), nurses/midwives (22.5%) and pharmaceutical staff (19.2%). They worked in teaching hospitals (23.3%), general hospitals (30.8%) and community hospitals (45.8%). Vaccine uptake was 73.3%, with 53.3% fully vaccinated and only 4.6% receiving a booster dose. However, 42.1% exhibited vaccine hesitancy, mainly due to concerns about side effects (52.2%). While 55.0% would recommend the vaccine, only 46.3% felt confident addressing patient questions. Age was positively correlated with vaccine uptake: HCWs aged 35–44 years, 45–54 years and 55–65 years were 1.60, 1.68 and 1.78, respectively times more likely to be vaccinated, respectively, compared to those aged 22–34 years. Conclusion: Vaccine hesitancy (25%) and low booster uptake (4.6%) highlight the need for targeted education and pharmacovigilance. Strengthening HCWs vaccine knowledge and trust is essential for epidemic control. Contribution: This study underscores the importance of Ministry of Health-led interventions to improve HCWs vaccination rates in Africa.